|
1
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bruix J and Sherman M; American
Association for the Study of Liver Diseases, : Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Faber W, Seehofer D, Neuhaus P, Stockmann
M, Denecke T, Kalmuk S, Warnick P and Bahra M: Repeated liver
resection for recurrent hepatocellular carcinoma. J Gastroenterol
Hepatol. 26:1189–1194. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gauthier A and Ho M: Role of sorafenib in
the treatment of advanced hepatocellular carcinoma: An update.
Hepatol Res. 43:147–154. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Desar IM, Mulder SF, Stillebroer AB, van
Spronsen DJ, van der Graaf WT, Mulders PF and van Herpen CM: The
reverse side of the victory: Flare up of symptoms after
discontinuation of sunitinib or sorafenib in renal cell cancer
patients. A report of three cases. Acta Oncol. 48:927–931. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang W, Sun HC, Wang WQ, Zhang QB, Zhuang
PY, Xiong YQ, Zhu XD, Xu HX, Kong LQ, Wu WZ, et al: Sorafenib
down-regulates expression of HTATIP2 to promote invasiveness and
metastasis of orthotopic hepatocellular carcinoma tumors in mice.
Gastroenterology. 143:1641–1649.e5. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bharti R, Dey G and Mandal M: Cancer
development, chemoresistance, epithelial to mesenchymal transition
and stem cells: A snapshot of IL-6 mediated involvement. Cancer
Lett. 375:51–61. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lanton T, Shriki A, Nechemia-Arbely Y,
Abramovitch R, Levkovitch O, Adar R, Rosenberg N, Paldor M,
Goldenberg D, Sonnenblick A, et al: Interleukin 6-dependent genomic
instability heralds accelerated carcinogenesis following liver
regeneration on a background of chronic hepatitis. Hepatology.
65:1600–1611. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chang TS, Wu YC, Chi CC, Su WC, Chang PJ,
Lee KF, Tung TH, Wang J, Liu JJ, Tung SY, et al: Activation of
IL6/IGFIR confers poor prognosis of HBV-related hepatocellular
carcinoma through induction of OCT4/NANOG expression. Clin Cancer
Res. 21:201–210. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mitra A, Yan J, Xia X, Zhou S, Chen J,
Mishra L and Li S: IL6-mediated inflammatory loop reprograms normal
to epithelial-mesenchymal transition+ metastatic cancer
stem cells in preneoplastic liver of transforming growth factor
beta-deficient β2-spectrin +/− mice. Hepatology.
65:1222–1236. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wan S, Zhao E, Kryczek I, Vatan L,
Sadovskaya A, Ludema G, Simeone DM, Zou W and Welling TH:
Tumor-associated macrophages produce interleukin 6 and signal via
STAT3 to promote expansion of human hepatocellular carcinoma stem
cells. Gastroenterology. 147:1393–1404. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sheng T, Wang B, Wang SY, Deng B, Qu L, Qi
XS, Wang XL, Deng GL and Sun X: The relationship between serum
interleukin-6 and the recurrence of hepatitis B virus related
hepatocellular carcinoma after curative resection. Medicine
(Baltimore). 94:e9412015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kao JT, Feng CL, Yu CJ, Tsai SM, Hsu PN,
Chen YL and Wu YY: IL-6, through p-STAT3 rather than p-STAT1,
activates hepatocarcinogenesis and affects survival of
hepatocellular carcinoma patients: A cohort study. BMC
Gastroenterol. 15:502015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Prieto-García E, Díaz-García CV,
García-Ruiz I and Agulló-Ortuño MT: Epithelial-to-mesenchymal
transition in tumor progression. Med Oncol. 34:1222017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ma JL, Zeng S, Zhang Y, Deng GL and Shen
H: Epithelial-mesenchymal transition plays a critical role in drug
resistance of hepatocellular carcinoma cells to oxaliplatin. Tumour
Biol. 37:6177–6184. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kodama T, Newberg JY, Kodama M, Rangel R,
Yoshihara K, Tien JC, Parsons PH, Wu H, Finegold MJ, Copeland NG
and Jenkins NA: Transposon mutagenesis identifies genes and
cellular processes driving epithelial-mesenchymal transition in
hepatocellular carcinoma. Proc Natl Acad Sci USA. 113:E3384–E3393.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu QD, Chen W, Yan TL, Ma T, Chen CL,
Liang C, Zhang Q, Xia XF, Liu H, Zhi X, et al: NSC 74859 enhances
doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal
transition in hepatocellular carcinoma cells. Cancer Lett.
325:207–213. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Giannelli G, Koudelkova P, Dituri F and
Mikulits W: Role of epithelial to mesenchymal transition in
hepatocellular carcinoma. J Hepatol. 65:798–808. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sullivan NJ, Sasser AK, Axel AE, Vesuna F,
Raman V, Ramirez N, Oberyszyn TM and Hall BM: Interleukin-6 induces
an epithelial-mesenchymal transition phenotype in human breast
cancer cells. Oncogene. 28:2940–2947. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yadav A, Kumar B, Datta J, Teknos TN and
Kumar P: IL-6 promotes head and neck tumor metastasis by inducing
epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling
pathway. Mol Cancer Res. 9:1658–1667. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rokavec M, Öner MG, Li H, Jackstadt R,
Jiang L, Lodygin D, Kaller M, Horst D, Ziegler PK, Schwitalla S, et
al: IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated
colorectal cancer invasion and metastasis. J Clin Invest.
124:1853–1867. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhuang PY, Zhang KW, Wang JD, Zhou XP, Liu
YB, Quan ZW and Shen J: Effect of TALEN-mediated IL-6 knockout on
cell proliferation, apoptosis, invasion and anti-cancer therapy in
hepatocellular carcinoma (HCC-LM3) cells. Oncotarget.
8:77915–77927. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cai H, Zhu XD, Ao JY, Ye BG, Zhang YY,
Chai ZT, Wang CH, Shi WK, Cao MQ, Li XL and Sun HC:
Colony-stimulating factor-1-induced AIF1 expression in
tumor-associated macrophages enhances the progression of
hepatocellular carcinoma. Oncoimmunology. 6:e13332132017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang YY, Kong LQ, Zhu XD, Cai H, Wang CH,
Shi WK, Cao MQ, Li XL, Li KS, Zhang SZ, et al: CD31 regulates
metastasis by inducing epithelial-mesenchymal transition in
hepatocellular carcinoma via the ITGB1-FAK-Akt signaling pathway.
Cancer Lett. 429:29–40. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang D, Zhu W, Wang Y, Sun C, Zhang KQ
and Yang J: Molecular tools for functional genomics in filamentous
fungi: Recent advances and new strategies. Biotechnol Adv.
31:1562–1574. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Katsuyama T, Akmammedov A, Seimiya M, Hess
SC, Sievers C and Paro R: An efficient strategy for TALEN-mediated
genome engineering in Drosophila. Nucleic Acids Res. 41:e1632013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wilhelm S, Carter C, Lynch M, Lowinger T,
Dumas J, Smith RA, Schwartz B, Simantov R and Kelley S: Discovery
and development of sorafenib: A multikinase inhibitor for treating
cancer. Nat Rev Drug Discov. 5:835–844. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gedaly R, Angulo P, Hundley J, Daily MF,
Chen C, Koch A and Evers BM: PI-103 and sorafenib inhibit
hepatocellular carcinoma cell proliferation by blocking
Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res.
30:4951–4958. 2010.PubMed/NCBI
|
|
34
|
Huang XY, Ke AW, Shi GM, Zhang X, Zhang C,
Shi YH, Wang XY, Ding ZB, Xiao YS, Yan J, et al: αB-crystallin
complexes with 14-3-3ζ to induce epithelial-mesenchymal transition
and resistance to sorafenib in hepatocellular carcinoma.
Hepatology. 57:2235–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dazert E, Colombi M, Boldanova T, Moes S,
Adametz D, Quagliata L, Roth V, Terracciano L, Heim MH, Jenoe P and
Hall MN: Quantitative proteomics and phosphoproteomics on serial
tumor biopsies from a sorafenib-treated HCC patient. Proc Natl Acad
Sci USA. 113:1381–1386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lourenco AR and Coffer PJ: SOX4: Joining
the master regulators of epithelial-to-mesenchymal transition?
Trends Cancer. 3:571–582. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Barrallo-Gimeno A and Nieto MA: The Snail
genes as inducers of cell movement and survival: Implications in
development and cancer. Development. 132:3151–3161. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Guo Y, Xu F, Lu T, Duan Z and Zhang Z:
Interleukin-6 signaling pathway in targeted therapy for cancer.
Cancer Treat Rev. 38:904–910. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shariat SF, Andrews B, Kattan MW, Kim J,
Wheeler TM and Slawin KM: Plasma levels of interleukin-6 and its
soluble receptor are associated with prostate cancer progression
and metastasis. Urology. 58:1008–1015. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Llovet JM, Brú C and Bruix J: Prognosis of
hepatocellular carcinoma: The BCLC staging classification. Semin
Liver Dis. 19:329–338. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yau T, Tang VY, Yao TJ, Fan ST, Lo CM and
Poon RT: Development of Hong Kong liver cancer staging system with
treatment stratification for patients with hepatocellular
carcinoma. Gastroenterology. 146:1691–1700.e3. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang BW, Liang Y, Xia JL, Sun HC, Wang L,
Zhang JB, Tang ZY, Liu KD, Chen J, Xue Q, et al: Biological
characteristics of fluorescent protein-expressing human
hepatocellular carcinoma xenograft model in nude mice. Eur J
Gastroenterol Hepatol. 20:1077–1084. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mir N, Jayachandran A, Dhungel B, Shrestha
R and Steel JC: Epithelial-to-mesenchymal transition: A mediator of
sorafenib resistance in advanced hepatocellular carcinoma. Curr
Cancer Drug Targets. 17:698–706. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang PF, Li KS, Shen YH, Gao PT, Dong ZR,
Cai JB, Zhang C, Huang XY, Tian MX, Hu ZQ, et al: Galectin-1
induces hepatocellular carcinoma EMT and sorafenib resistance by
activating FAK/PI3K/AKT signaling. Cell Death Dis. 7:e22012016.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Korkaya H, Kim GI, Davis A, Malik F, Henry
NL, Ithimakin S, Quraishi AA, Tawakkol N, D'Angelo R, Paulson AK,
et al: Activation of an IL6 inflammatory loop mediates trastuzumab
resistance in HER2+ breast cancer by expanding the cancer stem cell
population. Mol Cell. 47:570–584. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang
W, Xiong YQ, Wu WZ, Wang L, Tang ZY and Sun HC: High expression of
macrophage colony-stimulating factor in peritumoral liver tissue is
associated with poor survival after curative resection of
hepatocellular carcinoma. J Clin Oncol. 26:2707–2716. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yeung OW, Lo CM, Ling CC, Qi X, Geng W, Li
CX, Ng KT, Forbes SJ, Guan XY, Poon RT, et al: Alternatively
activated (M2) macrophages promote tumour growth and invasiveness
in hepatocellular carcinoma. J Hepatol. 62:607–616. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Nguyen DP, Li J and Tewari AK:
Inflammation and prostate cancer: The role of interleukin 6 (IL-6).
BJU Int. 113:986–992. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Rossi JF, Négrier S, James ND, Kocak I,
Hawkins R, Davis H, Prabhakar U, Qin X, Mulders P and Berns B: A
phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6
monoclonal antibody, in metastatic renal cell cancer. Br J Cancer.
103:1154–1162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Coward J, Kulbe H, Chakravarty P, Leader
D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J,
Vermeulen J, et al: Interleukin-6 as a therapeutic target in human
ovarian cancer. Clin Cancer Res. 17:6083–6096. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Moreau P, Harousseau JL, Wijdenes J,
Morineau N, Milpied N and Bataille R: A combination of
anti-interleukin 6 murine monoclonal antibody with dexamethasone
and high-dose melphalan induces high complete response rates in
advanced multiple myeloma. Br J Haematol. 109:661–664. 2000.
View Article : Google Scholar : PubMed/NCBI
|
